001021216 001__ 1021216
001021216 005__ 20250204113752.0
001021216 0247_ $$2doi$$a10.1007/s00414-023-03146-3
001021216 0247_ $$2ISSN$$a0367-0031
001021216 0247_ $$2ISSN$$a0044-3433
001021216 0247_ $$2ISSN$$a0937-9827
001021216 0247_ $$2ISSN$$a1437-1596
001021216 0247_ $$2datacite_doi$$a10.34734/FZJ-2024-00657
001021216 0247_ $$2pmid$$a38214738
001021216 0247_ $$2WOS$$aWOS:001141933800001
001021216 037__ $$aFZJ-2024-00657
001021216 082__ $$a610
001021216 1001_ $$0P:(DE-HGF)0$$aEsdar, Nicole$$b0
001021216 245__ $$aCardiac effects of 5F-Cumyl-PEGACLONE
001021216 260__ $$aGetzville, NY$$bHeinOnline$$c2024
001021216 3367_ $$2DRIVER$$aarticle
001021216 3367_ $$2DataCite$$aOutput Types/Journal article
001021216 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1714983716_28930
001021216 3367_ $$2BibTeX$$aARTICLE
001021216 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001021216 3367_ $$00$$2EndNote$$aJournal Article
001021216 520__ $$aSynthetic cannabinoids become increasingly popular as a supposedly safe and legal alternative to cannabis. In order to circumvent the German New Psychoactive Substances Law, producers of so-called herbal mixtures rapidly design new substances with structural alterations that are not covered by the law. Acting as full agonists not only at the cannabinoid receptors 1 and 2, synthetic cannabinoids might have not only desired mental but also serious physical adverse effects. However, knowledge of adverse effects of specific substances is sparse and incomplete. This also accounts for 5F-Cumyl-PEGACLONE, a synthetic cannabinoid, which has been detected regularly in Germany in recent years. By using an animal model, the isolated perfused Langendorff heart, the study at hand aimed on finding out more about possible cardiovascular adverse effects of 5F-Cumyl-PEGACLONE. Hearts of male Wistar rats, which were excised postmortem, were exposed to two different concentrations of 5F-Cumyl-PEGACLONE: 13 hearts were exposed to 50 ng/ml and 12 hearts were exposed to 100 ng/ml. Thirteen control hearts were merely exposed to an additional amount of buffer solution. Functional parameters heart rate, minimal and maximum left ventricular pressure and coronary flow were documented at pre-defined time points during and after the administration of 5F-Cumyl-PEGACLONE/additional buffer solution. Electrocardiograms (ECGs) were documented throughout the experiments and evaluated afterwards. Kruskal–Wallis analysis was performed for each functional parameter as well as for the duration of the QRS complexes and the duration of RR intervals as derived from the ECGs. Furthermore, a multivariate analysis, comprising all functional and ECG parameters, was performed. Kruskal–Wallis analysis revealed only single significant p-values for QRS duration and minimum left ventricular pressure that did not pass a Bonferroni test. The results of the multivariate approach were also comparably homogeneous, but still the model correctly recognized hearts exposed to 100 ng/ml of 5F-Cumyl-PEGACLONE more often than hearts exposed to the low concentration of 5F-Cumyl-PEGACLONE or additional buffer solution. Evaluation of the ECGs presented single cases of ST depression and QT prolongation. Though certainly not unambiguous, these findings support the assumption that 5F-Cumyl-PEGACLONE can cause severe, if not lethal, cardiac adverse effects like arrhythmias or myocardial infarctions especially if it is consumed in combination with other drugs like alcohol or if the consumer suffers from pre-existing heart diseases.
001021216 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001021216 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001021216 7001_ $$0P:(DE-HGF)0$$aPawlik, Evelyn$$b1
001021216 7001_ $$0P:(DE-Juel1)131678$$aEickhoff, Simon B.$$b2
001021216 7001_ $$0P:(DE-HGF)0$$aRaupach, Annika$$b3
001021216 7001_ $$0P:(DE-HGF)0$$aRitz-Timme, Stefanie$$b4
001021216 7001_ $$0P:(DE-HGF)0$$aMayer, Felix$$b5$$eCorresponding author
001021216 773__ $$0PERI:(DE-600)1459222-8$$a10.1007/s00414-023-03146-3$$p823-831$$tInternational journal of legal medicine$$v138$$x0367-0031$$y2024
001021216 8564_ $$uhttps://juser.fz-juelich.de/record/1021216/files/s00414-023-03146-3.pdf$$yOpenAccess
001021216 8564_ $$uhttps://juser.fz-juelich.de/record/1021216/files/s00414-023-03146-3.gif?subformat=icon$$xicon$$yOpenAccess
001021216 8564_ $$uhttps://juser.fz-juelich.de/record/1021216/files/s00414-023-03146-3.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
001021216 8564_ $$uhttps://juser.fz-juelich.de/record/1021216/files/s00414-023-03146-3.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
001021216 8564_ $$uhttps://juser.fz-juelich.de/record/1021216/files/s00414-023-03146-3.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
001021216 909CO $$ooai:juser.fz-juelich.de:1021216$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001021216 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131678$$aForschungszentrum Jülich$$b2$$kFZJ
001021216 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)131678$$a HHU Düsseldorf$$b2
001021216 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001021216 9141_ $$y2024
001021216 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001021216 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
001021216 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
001021216 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
001021216 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
001021216 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001021216 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
001021216 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
001021216 920__ $$lyes
001021216 9201_ $$0I:(DE-Juel1)INM-7-20090406$$kINM-7$$lGehirn & Verhalten$$x0
001021216 980__ $$ajournal
001021216 980__ $$aVDB
001021216 980__ $$aUNRESTRICTED
001021216 980__ $$aI:(DE-Juel1)INM-7-20090406
001021216 9801_ $$aFullTexts